Wedbush analyst Andreas Argyrides downgraded Albireo Pharma (ALBO) to Neutral from Outperform with a price target of $42, down from $53. The analyst notes Ipsen (IPSEY) and Albireo announced the companies have entered into an agreement under which Ipsen acquires Albireo in a cash tender offer for $42.00/share, a +104% premium to Albireo’s 1 month volume-weighted average price of $20.60.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ALBO: